Recent Publications

Braendstrup P, Levine B.L., Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020 Feb;22(2):57-69. doi: 10.1016/j.jcyt.2019.12.004. Epub 2020 Feb 1. Review.

Cerrano M, Ruella M, Miguel-Angel Perales, Candida Vitale, Danilo G. Faraci, Luisa Giaccone, Marta Coscia, Molly Maloy, Miriam Sanchez-Escamilla, Hesham Elsabah, Afraa Fadul, Enrico Maffini, Gianfranco Pittari, Benedetto Bruno. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research into Clinical Practice. Frontiers in Immunotherapy 2020 provisionally accepted

Ruella M, Barrett D.M., Shestova O, Perazzelli J, Posey, Jr. A.D, Hong SJ, Kozlowski M, Lacey S.F., Melenhorst J.J., June C.J., Gill S A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. Blood 2019 Nov 8. Blood.2019001859

Singh N, Lee Y, Ravikumar P, Shestova O, Hayer K, Hong S, Lu X, Pajarillo R, Agarwal S, Kuramitsu S, Orlando E, Mueller K, Good C, Berger S.L., Shalem O, Weitzman M, Frey N, Maude S, Grupp S, June C, Gill S, and Ruella M. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. Cancer Discovery 2020 SELECTED AS THE COVER OF THE ISSUE

Klichinsky M,  Ruella M, Shestova O, Best A, Zeeman M, Schmierer M, Gabrusciewicz K, Anderson N, Petty N, Cummins K, Shen F, Shan X, Lu X, Veliz K, Blouch K, Kenderian S, Kim M.Y., O’Connor R, Wallace S, Kozlowski M, Marchione D.M., Shestov M, Garcia B.A., June C.J., Gill S. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology 2020

Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M.: Novel Immunotherapies for T Cell Lymphoma and Leukemia. Curr Hematol Malig Rep. Oct 13 2018.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 24(10):1499-1503, Oct 2018.

Ruella Marco, June Carl H: Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. Molecular therapy: the journal of the American Society of Gene Therapy 26(6): 1401-1403, Jun 2018.

Singh N, Shi J, June CH, Ruella M.: Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. Curr Hematol Malig Rep 12(6): 522-529, Dec 2017.

Ruella M, Kenderian SS.: Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. BioDrugs 31(6): 473-481, Dec 2017.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M,  Wasik MA, June CH, Gill S. Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Disc 2017 Oct;7(10):1154-1167

Ruella M, Barrett DM, Kenderian SS, Shestova O, Klichinsky M., Hofmann TJ, Perazzelli J, Aikawa V, Nazimuddin F, Kozlowsky M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJD, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, and Gill S. A Novel Strategy for Preventing Antigen-Loss Relapses after CD19-directed Immunotherapies. Journal of Clinical Investigation, 2016 Aug 29. pii: 87366. doi: 10.1172/JCI87366

Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF,  June CH, and Gill S. A Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells (CART) for B cell neoplasms. Leukemia. 2016 Sep 28. doi: 10.1038/leu.2016.262.

Ruella M, Kenderian SS, Shestova O,  Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky K, Kawalekar OU, Lacey SF, Milone M, Mato AR, Schuster SJ, Kalos M, June CH, Wasik MA: The Addition of the BTK inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016 Jan 27.

Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C and Devizzi L. Addition of Rituximab to Involved-Field Radiotherapy Prolongs Progression-Free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):783-91.

Kenderian SS*, Ruella M*, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S. CD33 Specific Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity against Human Acute Myeloid Leukemia. Leukemia. 2015 Aug;29(8):1637-47.

Full list of publications: https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/47821257/?sort=date&direction=descending